BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $52,267,152 | -16.2% | 767,844 | +0.4% | 0.31% | -11.0% |
| Q2 2023 | $62,398,475 | +8.2% | 764,406 | -1.7% | 0.35% | +2.7% |
| Q1 2023 | $57,694,000 | -8.9% | 777,652 | +1.4% | 0.34% | -12.9% |
| Q4 2022 | $63,320,000 | +71.4% | 767,248 | +489.8% | 0.39% | +61.0% |
| Q3 2022 | $36,944,000 | -16.8% | 130,086 | +1.5% | 0.24% | -13.6% |
| Q2 2022 | $44,425,000 | -18.5% | 128,160 | +1.8% | 0.28% | 0.0% |
| Q1 2022 | $54,500,000 | -14.7% | 125,856 | +0.2% | 0.28% | -0.4% |
| Q4 2021 | $63,929,000 | +5.7% | 125,647 | +0.6% | 0.28% | +2.6% |
| Q3 2021 | $60,510,000 | -26.0% | 124,875 | -31.2% | 0.27% | -22.2% |
| Q2 2021 | $81,728,000 | +235.0% | 181,513 | +189.1% | 0.35% | +225.0% |
| Q1 2021 | $24,395,000 | +37.5% | 62,795 | +12.4% | 0.11% | +8.0% |
| Q4 2020 | $17,743,000 | +3.2% | 55,876 | -19.8% | 0.10% | +12.4% |
| Q3 2020 | $17,195,000 | -3.6% | 69,686 | -0.9% | 0.09% | -11.9% |
| Q2 2020 | $17,845,000 | +36.3% | 70,310 | +1.8% | 0.10% | +24.7% |
| Q1 2020 | $13,090,000 | +16.3% | 69,036 | +34.7% | 0.08% | +50.0% |
| Q4 2019 | $11,252,000 | +18.6% | 51,260 | +5.7% | 0.05% | +10.2% |
| Q3 2019 | $9,487,000 | -4.4% | 48,486 | +1.8% | 0.05% | -3.9% |
| Q2 2019 | $9,927,000 | +2.8% | 47,615 | -2.1% | 0.05% | 0.0% |
| Q1 2019 | $9,656,000 | +38.3% | 48,636 | +0.8% | 0.05% | +15.9% |
| Q4 2018 | $6,982,000 | -43.1% | 48,249 | -19.7% | 0.04% | -25.4% |
| Q3 2018 | $12,262,000 | +40.2% | 60,076 | +1.6% | 0.06% | +25.5% |
| Q2 2018 | $8,746,000 | +2.7% | 59,115 | +4.9% | 0.05% | +2.2% |
| Q1 2018 | $8,512,000 | +14.3% | 56,357 | -0.8% | 0.05% | +12.2% |
| Q4 2017 | $7,444,000 | +8.4% | 56,837 | +1.5% | 0.04% | +5.1% |
| Q3 2017 | $6,867,000 | +17.0% | 55,995 | +12.1% | 0.04% | +11.4% |
| Q2 2017 | $5,868,000 | +21.4% | 49,945 | +5.0% | 0.04% | +16.7% |
| Q1 2017 | $4,835,000 | +44.8% | 47,574 | +46.5% | 0.03% | +36.4% |
| Q4 2016 | $3,338,000 | -3.7% | 32,465 | +2.5% | 0.02% | -8.3% |
| Q3 2016 | $3,468,000 | -4.1% | 31,679 | -1.2% | 0.02% | -4.0% |
| Q2 2016 | $3,615,000 | +15.0% | 32,060 | -3.6% | 0.02% | +13.6% |
| Q1 2016 | $3,144,000 | -56.3% | 33,270 | -58.4% | 0.02% | -54.2% |
| Q4 2015 | $7,197,000 | +10.2% | 79,969 | +13.2% | 0.05% | +118.2% |
| Q3 2015 | $6,528,000 | +49.4% | 70,622 | +59.1% | 0.02% | -12.0% |
| Q2 2015 | $4,370,000 | +50.4% | 44,387 | +53.2% | 0.02% | +47.1% |
| Q1 2015 | $2,906,000 | -46.3% | 28,976 | -50.6% | 0.02% | -45.2% |
| Q4 2014 | $5,414,000 | – | 58,602 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |